ghk cu tripeptide GHK-CU – Research Peptide Argireline a no needle alternative GHK-Cu Topical: Evidence, Safety &

Importation may lead to customs seizures or additional scrutiny depending on local laws

A standard 6-week treatment protocol at 0.5 mg daily requires approximately 21 mg total, or about 4-5 vials

Growth hormone plays important roles in tissue repair, protein synthesis, and recovery

hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls

Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters